Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Impact of COVID-19 on AML treatment & management

Thomas Prebet • 11 Jun 2020
EHA 2020
Acute Myeloid Leukemia Leukemia

Thomas Prebet, MD, of the Yale School of Medicine, New Haven, CT, evaluates the impact of the COVID-19 pandemic on the treatment and management of acute myeloid leukemia (AML) patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Thomas Prebet

3:31
Risk stratified analysis of CPX-351 versus 7 + 3 in older adults with AML
Thomas Prebet • 18 Nov 2020
1:50
Hypomethylating agent based combinations in MDS
Thomas Prebet • 18 Nov 2020
2:19
AML: what to look forward to at ASH 2020
Thomas Prebet • 18 Nov 2020
1:19
New treatments for AML
Thomas Prebet • 7 Oct 2020

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals